1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis BAA seeks groundbreaking research in technologies at the intersection of artificial intelligence and biotechnology.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Universities, industry, and government laboratories are eligible. DARPA is interested in engaging first-time or non-traditional proposers. Confirm the full requirements in the official notice before applying.
The current listing shows standard BAA awards range from $500K to $20M. Multiple awards, accelerated award pathway for proposals under $2 million. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Biological Technologies Office Broad Agency Announcement (BAA) are due September 29, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Biological Technologies Office Broad Agency Announcement (BAA) is funded by Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs (NCI) is sponsored by National Cancer Institute (NCI) - NIH. The NCI SBIR and STTR programs support small businesses in developing innovative cancer technologies with strong potential to improve health outcomes. This includes therapeutics, diagnostics, imaging technologies, and tools for cancer biology research.
Research Infrastructure Programs - Research Centers is sponsored by Department of Health And Human Services. The Office of Research Infrastructure Programs (ORIP), within the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) in the NIH Office of the Director, supports extramural biomedical research by strengthening the infrastructure that enables scientific discovery. ORIP advances human health by fostering the development of critical research models, biomaterials, and technologies; expanding access to state-of-the-art instrumentation and facilities; supporting education and training programs; and assisting small businesses in translating innovative technologies. Through its two divisions, the Division of Comparative Medicine (DCM) and the Division of Construction and Instruments (DCI), ORIP plays a critical role in accelerating biomedical research nationwide. DCM develops and sustains essential research models and biological resources, manages the infrastructure required for their use and distribution, and provides training to ensure investigators have reliable access to high-quality models and facilities. DCI supports shared, cost-effective access to advanced scientific instrumentation, modernizing research facilities, and providing critical equipment that enables transformative biomedical discoveries. Together, DCM and DCI strengthen U.S. competitiveness and ensure the biomedical research community has the infrastructure necessary to address emerging health challenges, prevent disease, promote health, and advance foundational science. This listing is currently active. Program number: 93.3RC. Last updated on 2026-01-28.
Biological Technologies is sponsored by Defense Advanced Research Projects Agency (DARPA), Biological Technologies Office (BTO). Supports revolutionary research leveraging biological properties/processes to advance national security and protect warfighters; excludes incremental improvements. Key focus areas include advanced machine learning and AI for biological data and systems, combat casualty care, human performance optimization, bio-inspired materials, sensors, manufacturing, agricultural, ecological, and environmental security, biosafety, biosecurity, next-generation surveillance, and biomedical and biodefense technologies. Foreign companies may be eligible as DARPA aims for international collaboration for national security.
On June 3, 2026, four DARPA Biological Technologies Office SBIR topics close simultaneously — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Combined Phase I plus Phase II potential exceeds $6 million per company, and together they sketch a coherent strategy of distributed, autonomous, dual-species combat casualty care that depends on small businesses, not primes, to actually build.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleDARPA BTO pre-released four FY26 SBIR/STTR topics on April 30, 2026, with proposals due June 3. Two topics — SWiFT and EXPOSITION — offer Direct-to-Phase-II awards up to $1.5M, bypassing the standard Phase I gate. Here is what each topic is actually solving, why the DP2 structure matters, and how small biotech, surgical robotics, and battlefield-medicine teams should decide whether to compete.
Read article